Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 8/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 8/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.37 |
| ▸ | BRD4 | O60885 | 3/20 | 0.37 |
| ▸ | MET | P08581 | 3/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24316569 | 0.85 | CREBBP (0.43) | FGFR1FGFR3FGFR2CREBBPLRRK2 | |
| SCHEMBL29471176 | 0.84 | FGFR1 (0.43) | FGFR1FGFR3FGFR2CREBBPFGFR4 | |
| SCHEMBL24316696 | 0.84 | FGFR1 (0.43) | FGFR1FGFR3FGFR2CREBBPFGFR4 | |
| SCHEMBL24316676 | 0.84 | BRD4 (0.37) | CREBBPBRD4LRRK2 | |
| SCHEMBL29471161 | 0.84 | BRD4 (0.37) | CREBBPBRD4LRRK2 | |
| SCHEMBL24316573 | 0.83 | XDH (0.38) | BRD4 | |
| SCHEMBL29471148 | 0.83 | CREBBP (0.37) | FGFR1FGFR3FGFR2CREBBPBRD4 | |
| SCHEMBL24316675 | 0.83 | CREBBP (0.37) | FGFR1FGFR3FGFR2CREBBPBRD4 | |
| SCHEMBL24316602 | 0.83 | CREBBP (0.40) | FGFR1FGFR3FGFR2CREBBPFGFR4 | |
| SCHEMBL29471215 | 0.83 | CREBBP (0.40) | FGFR1FGFR3FGFR2CREBBPFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-10-12 | — | — | US | disclosed |
| WO-2022053967-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | EP300, HDAC1, BRD3 | FGFR1 1849/4885FGFR3 3451/4885FGFR2 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.